Anti-dsDNA antibodies: autoimmunity aimed at native DNA
Anti-double-stranded DNA antibodies are immune proteins that bind the body's own DNA. They are autoantibodies (anti-dsDNA) produced by B cells that have lost self-tolerance, often after nuclear material from dying cells is exposed. These antibodies circulate in the blood and recognize native double-stranded DNA (dsDNA) from the cell nucleus. They belong to the broader family of antinuclear antibodies (ANA). A dsDNA antibody blood test looks for these self-directed antibodies in a blood sample.
In the body, anti-dsDNA antibodies do not serve a normal protective role; they signal a misdirected immune response (loss of tolerance) against nuclear material. When they attach to DNA, they can form clusters with immune proteins (immune complexes) that trigger complement and inflammation, especially in the kidney's filtering units (glomeruli). This pattern is a hallmark of systemic lupus erythematosus (SLE) and related autoimmune activity. Finding anti-dsDNA in blood indicates that the immune system is targeting native DNA and that autoimmune inflammation driven by these complexes may be occurring. The test provides a direct window into this DNA-targeting arm of autoimmunity.
Why anti-dsDNA matters in lupus diagnosis and monitoring
Anti-double-stranded DNA (dsDNA) antibodies are immune proteins that mistakenly target your own DNA. They are a hallmark of systemic lupus erythematosus (SLE) and signal a breakdown in immune tolerance. When present, these antibodies form immune complexes that can inflame blood vessels and organs—especially the kidneys—so they matter across skin, joints, kidneys, brain, blood, and the cardiovascular system.
The anti-double-stranded DNA (dsDNA) antibody blood test measures immune proteins that bind native DNA. It matters because such antibodies indicate loss of self-tolerance and immune complexes that inflame vessels and organs, especially kidneys. This inflammation can affect energy, cognition, skin and joints, and renal and vascular function.
Negative, low, and high titers: how to read them
Most labs report results as negative, borderline, or positive; some use low, moderate, or high categories. In general, the healthiest "set point" is negative or undetectable, and trends over time are often more informative than a single value. Being in range suggests stable immune tolerance with minimal immune-complex burden. For most labs the within reference ranges position is at the negative or very low end, and in established lupus it suggests controlled disease activity.
When values are negative or very low, they reflect intact immune tolerance—little to no immune targeting of native DNA. Low values usually reflect little or no autoimmune targeting of DNA—what's expected in healthy immune regulation. People typically have no dsDNA-related symptoms. In someone already diagnosed with SLE, low or falling levels often parallel quieter disease and a lower likelihood of kidney or systemic flare. In people with known lupus, low or undetectable levels often align with quieter disease activity; across sexes, ages, and pregnancy, low values are typical and not linked to symptoms.
Higher values indicate active autoimmune targeting of DNA, immune-complex formation, and complement activation. High values usually reflect active systemic autoimmunity, most specifically systemic lupus erythematosus (SLE). This can drive fatigue, fevers, joint pain, photosensitive rashes, mouth ulcers, and—in the kidneys—protein in the urine, swelling, and rising blood pressure (lupus nephritis). Levels often track with disease flares and kidney involvement (lupus nephritis) and may coincide with low complement (C3/C4), cytopenias, rashes, serositis, or neuropsychiatric symptoms. Neurologic symptoms (headache, seizures), low blood counts, and vasculitic complications may appear. High titers are uncommon in drug-induced lupus and are rarely seen outside SLE, though children and pregnant individuals with SLE can also show rises during flares. Women are affected more often than men; during pregnancy, higher levels tend to track more active lupus and greater risk of nephritis and pregnancy complications. Children and teens with SLE often show higher titers and more renal involvement.
Assay differences and what a result cannot rule out
Interpretation varies by assay—ELISA is sensitive; Farr/Crithidia are more specific. Reference ranges differ; results fluctuate with disease activity. A negative test does not exclude SLE. Interpret with ANA, complement, and urinalysis; recent infections or biologics can transiently induce autoantibodies.
Pairing dsDNA with complement, ANA, and urinalysis
Big picture: dsDNA antibodies connect to the ANA profile, anti-Sm antibodies, complement (C3/C4), and urinalysis. They aid diagnosis and, importantly, help monitor disease activity and long-term risks—especially kidney and cardiovascular outcomes driven by chronic inflammation.
FAQs
A dsDNA antibody, or anti–double-stranded DNA antibody, is an autoantibody produced by the immune system that mistakenly targets the body’s own double-stranded DNA. This antibody is a hallmark of systemic lupus erythematosus (SLE) and is rarely found in healthy individuals. Its presence helps confirm a diagnosis of lupus, especially when combined with other tests like antinuclear antibody (ANA) and complement levels. High levels of dsDNA antibodies are closely linked to lupus activity, particularly kidney involvement (lupus nephritis), and can help distinguish SLE from other autoimmune diseases.
The dsDNA antibody test measures the amount of antibodies targeting double-stranded DNA in the blood. Rising dsDNA levels often indicate increased lupus activity or an impending flare, while falling levels suggest disease remission or effective treatment. Tracking dsDNA titers over time, alongside complement levels (C3, C4) and symptoms, allows healthcare providers to adjust treatment intensity and monitor for organ involvement, especially in the kidneys, skin, and joints.
Doctors may order a dsDNA antibody test when patients present with unexplained rashes, joint pain, fevers, fatigue, or other symptoms suggestive of systemic lupus erythematosus (SLE). The test is also used to clarify the cause of kidney problems, such as edema, foamy urine, or high blood pressure, and to investigate persistent inflammation or abnormal blood counts. It is especially useful when lupus is suspected but not yet confirmed.
dsDNA antibody results are reported as negative, borderline, or positive, sometimes with a titer value. Low or negative results indicate no significant immune targeting of DNA and a low risk of lupus-related tissue injury. High or positive results suggest active autoimmunity, immune complex formation, and increased risk of organ inflammation, especially in the kidneys. Interpretation depends on the assay used, lab cutoffs, and clinical context, and results are best understood alongside ANA, complement levels, and urinalysis.
dsDNA antibodies are strongly associated with lupus nephritis, a serious kidney complication of systemic lupus erythematosus (SLE). These antibodies form immune complexes that deposit in kidney tissues, triggering complement activation and inflammation. High dsDNA titers often precede or accompany kidney symptoms such as swelling, proteinuria, and reduced kidney function. Monitoring dsDNA levels helps detect kidney involvement early and guide treatment to protect renal health.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Orme, M. E., Voreck, A., Aksouh, R., & Schreurs, M. W. J. (2022). Anti-dsDNA testing specificity for systemic lupus erythematosus: A systematic review. The Journal of Applied Laboratory Medicine, 7(1), 221-239. https://doi.org/10.1093/jalm/jfab146
- Fu, S. M., Dai, C., Zhao, Z., & Gaskin, F. (2015). Anti-dsDNA antibodies are one of the many autoantibodies in systemic lupus erythematosus. F1000Research, 4, 939. https://doi.org/10.12688/f1000research.6875.1
- Kądziela, M., Fijałkowska, A., Kraska-Gacka, M., & Woźniacka, A. (2025). The art of interpreting antinuclear antibodies (ANAs) in everyday practice. Journal of Clinical Medicine, 14(15), 5322. https://doi.org/10.3390/jcm14155322
- Leuchten, N., Hoyer, A., Brinks, R., Schoels, M., Schneider, M., Smolen, J., Johnson, S. R., Daikh, D., Dörner, T., Aringer, M., & Bertsias, G. (2018). Performance of antinuclear antibodies for classifying systemic lupus erythematosus: A systematic literature review and meta-regression of diagnostic data. Arthritis Care & Research, 70(3), 428-438. https://doi.org/10.1002/acr.23292
- Brigden, M. L. (1999). Clinical utility of the erythrocyte sedimentation rate. American Family Physician, 60(5), 1443-1450. https://pubmed.ncbi.nlm.nih.gov/10524488/






































.avif)
